Data as of Apr 15
| -0.43 / -7.60%|
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction (CEE) technology for the detection and analysis of circulating tumor DNA tests. The CEE technology is an internally invented and developed microfluidics-based CTC capture and analysis platform used by clinicians by providing real-time biomarker monitoring. It also utilizes patented technologies to deliver clinically relevant oncology laboratory tests to physicians that provide advanced prognostic and predictive assessments for guiding the course of treating patients. The company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.
|Michael W. Nall||President, Chief Executive Officer & Director|
|William G. Kachioff||Chief Financial Officer & Senior VP-Finance|
|Farideh Z. Bischoff||VP-Translational Research & Clinical Development|
|Lyle J. Arnold||Chief Scientific Officer & Senior VP-Research|
|Philip D. Cotter||Vice President & Director-Clinical Laboratories|